A website to provide support for people who have or have had any type of cancer, for their caregivers and for their family members.
Results 1 to 3 of 3

Thread: JAMA Abstract of Results from a Saw Palmetto Trial

Threaded View

  1. #1
    Top User pbj11's Avatar
    Join Date
    May 2007

    JAMA Abstract of Results from a Saw Palmetto Trial

    JAMA. 2011;306(12):1344-1351. doi: 10.1001/jama.2011.1364
    Effect of Increasing Doses of Saw Palmetto Extract on Lower Urinary Tract Symptoms

    A Randomized Trial
    Michael J. Barry, MD; Sreelatha Meleth, PhD; Jeannette Y. Lee, PhD; Karl J. Kreder, MD, MBA; Andrew L. Avins, MD, MPH; J. Curtis Nickel, MD; Claus G. Roehrborn, MD; E. David Crawford, MD; Harris E. Foster, Jr, MD; Steven A. Kaplan, MD; Andrew McCullough, MD; Gerald L. Andriole, MD; Michael J. Naslund, MD; O. Dale Williams, PhD; John W. Kusek, PhD; Catherine M. Meyers, MD; Joseph M. Betz, PhD; Alan Cantor, PhD; Kevin T. McVary, MD for the Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Study GroupAuthor Affiliations

    • Author Affiliations: Department of Medicine, Massachusetts General Hospital, Boston (Dr Barry); Division of Preventive Medicine, University of Alabama, Birmingham (Drs Meleth, Williams, and Cantor); Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock (Dr Lee); Department of Urology, University of Iowa, Iowa City (Dr Kreder); Division of Research, Northern California Kaiser Permanente, Oakland (Dr Avins); Department of Urology, Queen's University, Kingston, Ontario, Canada (Dr Nickel); Department of Urology, University of Texas Southwestern Medical Center, Dallas (Dr Roehrborn); Section of Urologic Oncology, University of Colorado, Denver (Dr Crawford); Section of Urology, Yale University School of Medicine, New Haven, Connecticut (Dr Foster); Department of Urology, Weill Cornell Medical College, New York, New York (Dr Kaplan); Urology Associates, New York University, New York, New York (Dr McCullough); Division of Urologic Surgery, Washington University School of Medicine, St Louis, Missouri (Dr Andriole); Maryland Prostate Center, University of Maryland, Baltimore (Dr Naslund); National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland (Dr Kusek); National Center for Complementary and Alternative Medicine, Bethesda, Maryland (Dr Meyers); National Institutes of Health Office of Dietary Supplements, Bethesda, Maryland (Dr Betz); and Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Dr McVary).


    Context Saw palmetto fruit extracts are widely used for treating lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH); however, recent clinical trials have questioned their efficacy, at least at standard doses (320 mg/d).
    Objective To determine the effect of saw palmetto extract (Serenoa repens, from saw palmetto berries) at up to 3 times the standard dose on lower urinary tract symptoms attributed to BPH.
    Design, Setting, and Participants A double-blind, multicenter, placebo-controlled randomized trial at 11 North American clinical sites conducted between June 5, 2008, and October 10, 2010, of 369 men aged 45 years or older, with a peak urinary flow rate of at least 4 mL/s, an American Urological Association Symptom Index (AUASI) score of between 8 and 24 at 2 screening visits, and no exclusions.
    Interventions One, 2, and then 3 doses (320 mg/d) of saw palmetto extract or placebo, with dose increases at 24 and 48 weeks.
    Main Outcome Measures Difference in AUASI score between baseline and 72 weeks. Secondary outcomes included measures of urinary bother, nocturia, peak uroflow, postvoid residual volume, prostate-specific antigen level, participants' global assessments, and indices of sexual function, continence, sleep quality, and prostatitis symptoms.
    Results Between baseline and 72 weeks, mean AUASI scores decreased from 14.42 to 12.22 points (−2.20 points; 95% CI, −3.04 to −0.36) with saw palmetto extract and from 14.69 to 11.70 points (−2.99 points; 95% CI, −3.81 to −2.17) with placebo. The group mean difference in AUASI score change from baseline to 72 weeks between the saw palmetto extract and placebo groups was 0.79 points favoring placebo (upper bound of the 1-sided 95% CI most favorable to saw palmetto extract was 1.77 points, 1-sided P = .91). Saw palmetto extract was no more effective than placebo for any secondary outcome. No clearly attributable adverse effects were identified.
    Conclusion Increasing doses of a saw palmetto fruit extract did not reduce lower urinary tract symptoms more than placebo.
    Trial Registration clinicaltrials.gov Identifier: NCT00603304
    Last edited by pbj11; 12-30-2011 at 06:10 PM.


Similar Threads

  1. First results from IMA950 trial
    By NikosF in forum Brain Tumors Forum
    Replies: 2
    Last Post: 12-01-2012, 01:06 PM
  2. TH-302 Trial Results
    By lancepeace in forum Pancreatic Cancer Forum
    Replies: 0
    Last Post: 02-21-2012, 02:08 PM
  3. regorafenib Phase III trial Results
    By lancepeace in forum Colon Cancer and Rectal Cancer Forum
    Replies: 1
    Last Post: 01-19-2012, 01:00 AM
  4. Metastatic Melanoma PV-10 Trial Results Encouraging
    By HaoleBoy in forum Melanoma and Skin Cancer Forum
    Replies: 0
    Last Post: 10-28-2009, 12:39 AM
  5. horrifying trial results for 2nd generation Ablatherm
    By Replicant in forum Prostate Cancer Forum
    Replies: 5
    Last Post: 04-02-2009, 09:10 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts